Prostate Cancer

Rucaparib receives full FDA approval for treating metastatic castration-resistant prostate cancer, offering a vital chemotherapy-free option for patients.

FDA approves a new treatment combining niraparib and abiraterone for BRCA2-mutated metastatic prostate cancer, enhancing patient outcomes.

JANX007 shows promising efficacy and manageable safety in treating metastatic castration-resistant prostate cancer, with significant PSA reductions and durable responses.

Che-Kai Tsao, MD, MS, discusses new approaches that could change the standard of care for metastatic hormone-sensitive prostate cancer.

The IsoPSA test revolutionizes prostate cancer diagnosis, enhancing risk assessment and reducing unnecessary biopsies for men with elevated PSA levels.

Recent polling shows oncologists' changing inclination in treatment for metastatic hormone-sensitive prostate cancer (mHSPC) based on tolerability profiles.

Che-Kai Tsao, MD, MS, discusses the current state of treatment for metastatic hormone-sensitive prostate cancer.

New research reveals that radiotherapy benefits prostate cancer patients with fewer metastases, refining treatment strategies for advanced cases.

A groundbreaking study reveals that less frequent dosing of pasritamig enhances immune response in advanced prostate cancer, challenging traditional treatment assumptions.

A recent study reveals that medication burden significantly increases acute care use in older metastatic prostate cancer patients on androgen receptor inhibitors.

Lutetium Lu 177 vipivotide tetraxetan significantly enhances survival in metastatic hormone-sensitive prostate cancer when combined with standard therapies, according to recent trial results.

During a live event, Cora N. Sternberg, MD, discussed tolerability outcomes from the ARANOTE trial and distinguishing aspects of androgen receptor pathway inhibitors.

During a live event, Cora N. Sternberg, MD, discussed the development of androgen receptor pathway inhibitors and takeaways from the ARANOTE trial in hormone-sensitive prostate cancer.

New findings from the EMBARK trial reveal enzalutamide significantly reduces mortality risk in high-risk prostate cancer patients, enhancing treatment options.

New research reveals enzalutamide combined with leuprolide significantly enhances survival rates in high-risk prostate cancer patients, setting a new standard of care.

New research shows that adding apalutamide to androgen deprivation therapy significantly improves outcomes for patients with recurrent prostate cancer.

New trial results reveal capivasertib enhances survival in advanced prostate cancer, offering hope for patients with PTEN deficiency.

Patients with metastatic hormone-sensitive prostate cancer report stable health-related quality of life while receiving niraparib and abiraterone acetate in the AMPLITUDE trial.

A phase 1/2 trial shows saruparib combined with ARPI offers high response rates and manageable safety in metastatic prostate cancer patients.

A new treatment regimen for metastatic prostate cancer shows significant reductions in severe adverse events, offering a promising alternative for patients.

New findings reveal that combining niraparib with abiraterone significantly extends progression-free survival in patients with HRR-altered metastatic prostate cancer.

Recent analysis reveals that rectal spacers significantly lower recurrence rates in prostate cancer patients undergoing radiation therapy, enhancing treatment outcomes.

A phase 2 trial reveals PSMA-PET–guided salvage radiotherapy significantly enhances cancer control in patients with prostate cancer post surgery.

Prostate cancer advancements highlight genetic mutations' impact on therapy and family health, emphasizing early treatment strategies for better outcomes.